EP Patent

EP2361609A1 — Sustained release small molecule drug formulation

Assigned to Durect Corp · Expires 2011-08-31 · 15y expired

What this patent protects

The invention relates to an injectable depot formulation, comprising: a biocompatible polymer; an organic solvent combined with the biocompatible polymer to form a viscous gel; and a small molecule drug incorporated in the viscous gel. More specifically risperidone is disclosed w…

USPTO Abstract

The invention relates to an injectable depot formulation, comprising: a biocompatible polymer; an organic solvent combined with the biocompatible polymer to form a viscous gel; and a small molecule drug incorporated in the viscous gel. More specifically risperidone is disclosed with polyactide polymer or a copolymer based on lactic acid and glycolic acid together with benzyl alcohol, benzyl benzoate, ethyl benzoate, ethanol, triacetin or N-methyl-2-pyrrolidone for psychotherapeutic treatments.

Drugs covered by this patent

Patent Metadata

Patent number
EP2361609A1
Jurisdiction
EP
Classification
—
Expires
2011-08-31
Drug substance claim
No
Drug product claim
No
Assignee
Durect Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.